Table 1.

Baseline characteristics of 626 patients with newly diagnosed MM

Characteristicn/N (%)Median (range)
Age at diagnosis, y  57 (26-83) 
Male 382/626 (61)  
ISS stage   
 I 122/626 (19)  
 II 236/626 (38)  
 III 268/626 (43)  
Cytogenetics abnormalities by iFISH   
 High risk* 172/557 (31)  
 Standard risk 385/557 (69)  
M-component   
 IgG 307/626 (49)  
 IgA 151/626 (24)  
 Light chain 119/626 (19)  
 Other 49/626 (8)  
First-line therapy   
 IMiDs 236/626 (38)  
 PIs 401/626 (64)  
First-line transplantation§ 182/626 (29)  
Best response to first-line therapy   
 CR 265/626 (42)  
 VGPR 161/626 (26)  
 PR 133/626 (21)  
TBR, mo  3.1 (0.7-19.0) 
DBR, mo  21.2 (1.5-130.0) 
Characteristicn/N (%)Median (range)
Age at diagnosis, y  57 (26-83) 
Male 382/626 (61)  
ISS stage   
 I 122/626 (19)  
 II 236/626 (38)  
 III 268/626 (43)  
Cytogenetics abnormalities by iFISH   
 High risk* 172/557 (31)  
 Standard risk 385/557 (69)  
M-component   
 IgG 307/626 (49)  
 IgA 151/626 (24)  
 Light chain 119/626 (19)  
 Other 49/626 (8)  
First-line therapy   
 IMiDs 236/626 (38)  
 PIs 401/626 (64)  
First-line transplantation§ 182/626 (29)  
Best response to first-line therapy   
 CR 265/626 (42)  
 VGPR 161/626 (26)  
 PR 133/626 (21)  
TBR, mo  3.1 (0.7-19.0) 
DBR, mo  21.2 (1.5-130.0) 

iFISH, interphase fluorescent in situ hybridization.

*

High-risk cytogenetic abnormalities (CAs) were defined as the presence of 20% or more del(17p) or 10% or more t(4;14), t(14;16), or t(14;20) in screened plasma cells.

Standard-risk CAs defined by the absence of high-risk CAs.

A total of 11 patients who received IMiDs combined with PIs were counted twice.

§

First-line transplantation was defined as transplantation within 12 months of first-line therapy.

or Create an Account

Close Modal
Close Modal